Business

Exploring the Ripple Effects of Trump's Tariff Policies on the Indian Stock Market

Trump's Tariff Threats Stir Global Markets

Donald Trump's recent tariff threats have introduced a new wave of volatility across global stock markets, with India finding itself at the heart of the US president's trade realignment strategy. India currently faces a 9.5% tariff on US goods, a stark contrast to the 3% tariff imposed by the US on Indian products. This imbalance has put several key industries, including automobiles, pharmaceuticals, textiles, and steel, at significant risk.

What could be the impact of Trump's tariff flip flop on Indian stock market?

Foreign Investment Retreats Amidst Uncertainty

The Nifty index, despite a brief rally, remains 14% below its peak, with smallcaps entering bear market territory. The situation has been exacerbated by Foreign Institutional Investors (FIIs) pulling out over $15 billion in 2025 alone. Foreign Portfolio Investors (FPIs) have continued their selling spree in Indian equities, with total equity outflows reaching Rs 24,753 crore by March 7, marking a year-to-date total of Rs 1,37,354 crore in CY25.

India's Strategic Response to Trade Challenges

India's vulnerability to tariff hikes is evident, with the Indian Rupee weakening and foreign investment retreating due to slowdown concerns. Ross Maxwell of VT Markets highlights the potential severe impacts on India's automobile, pharmaceutical, textiles, and steel sectors. However, India's diplomatic approach, focusing on trade negotiations and tariff rationalization, could offer a way to mitigate these risks. YES Securities suggests reducing tariffs on US imports like steel and encouraging American companies such as Tesla to enter India as strategic moves against potential retaliatory tariffs.

Market Sentiment and Future Outlook

Dr. V.K. Vijayakumar of Geojit Financial Services views Trump's tariff moves as temporary negotiations rather than long-term impositions, acknowledging the potential harm to the US economy. Meanwhile, the pharmaceutical sector, holding 35% of the US market, faces short-term challenges but may benefit in the long term due to India's competitive advantage over China. Despite global uncertainties, Indian markets have shown resilience, with experts like Vinod Nair and Amisha Vora seeing the current dip as an investment opportunity amidst ongoing reforms and India's demographic advantage.